A new University of Georgia network meta-analysis finds tirzepatide sitting at the top of the weight-loss heap among commonly prescribed GLP-1 drugs for people without diabetes. At the highest doses studied, tirzepatide was tied to more than a 20% average reduction in body weight, compared with roughly 15% for semaglutide (Wegovy) and about 8% for liraglutide (Saxenda). The researchers also flag a big unknown: the review did not look at what happens to patients’ weight once they stop these medications, which leaves a major question mark for both clinicians and patients.
Study and findings
The team pooled results from 15 phase 3 randomized trials that together enrolled more than 14,000 adults without diabetes, according to a network meta-analysis published in Obesity. Using a Bayesian network comparison, the authors estimated percentage weight change by drug and dose and found the biggest average reductions with tirzepatide at the 10 to 15 mg regimens. The paper calls for more direct head-to-head trials and longer follow-up to really understand how durable the benefits are and how safety plays out over time.
How the drugs stacked up
University of Georgia researchers say tirzepatide’s apparent edge likely comes from its dual GIP and GLP-1 activity plus the higher doses tested, with the analysis showing that bigger doses generally meant bigger losses on the scale. “We were interested in finding which drug gives the most weight loss and doesn’t have higher rates of side effects like nausea and gastrointestinal problems. Tirzepatide seems to be the better option,” said Pooja Gokhale, the study’s corresponding author, as reported by UGA Today. The university’s coverage also notes a practical difference many patients care about: liraglutide is injected daily, while tirzepatide and semaglutide are taken once a week.
Head-to-head evidence
The UGA meta-analysis builds on a prior randomized head-to-head trial, SURMOUNT-5, that found tirzepatide produced about 20.2% average weight loss versus roughly 13.7% with semaglutide at 72 weeks, as published in the New England Journal of Medicine. That direct comparison has given clinicians the clearest signal so far that dual-agonist approaches can outperform single-target GLP-1 therapy for weight reduction in adults without diabetes. Safety profiles varied somewhat across trials, and investigators emphasize that patients still need individualized risk-benefit conversations, not a one-size-fits-all winner.
Pills versus injections
Oral GLP-1 pills have now joined the mix. The FDA approved Eli Lilly’s orforglipron (Foundayo) as an oral weight-loss option in April 2026, according to the agency. Still, the Obesity meta-analysis reports that in sensitivity checks, an oral 50 mg formulation did not beat tirzepatide’s effect and landed closer in efficacy to injectable semaglutide. For now, that suggests pills are not a straight swap for tirzepatide at its top doses. The authors note that as availability and pricing shift, patients and prescribers will be weighing the convenience of a pill against the extra percentage points of weight loss seen with the more potent injectables.
Side effects, dosing and unanswered questions
Across the trials and in the meta-analysis, gastrointestinal side effects such as nausea, vomiting and diarrhea show up frequently across the whole drug class, and how well patients tolerate those issues often determines whether they can stay on the higher doses. The UGA group underscores that they did not study what happens after treatment stops, so the extent of weight regain is still an open question that matters a lot for long-term planning. Patients are also advised to factor in how often each drug is taken, contraindications and possible drug interactions when they sit down with their clinicians to choose among options.
What this means for patients and insurers
Insurers and employers are already tweaking benefits as the GLP-1 market evolves. Cigna, for example, recently moved to end coverage for some GLP-1 weight-loss drugs for its own employees after it yanked a Wegovy-style weight-loss perk from its workforce. As oral drugs roll out more broadly and additional head-to-head data arrive, debates over access and cost are likely to heat up both at the pharmacy counter and in health plan design meetings.
For now, the new meta-analysis reinforces growing evidence that tirzepatide delivers the largest average weight reductions seen so far in adults without diabetes, but it does not answer lingering questions about long-term durability, safety and real-world access. Clinicians and patients are left to treat the trial data as one important input among many when picking a treatment plan, while keeping an eye out for new direct comparisons and longer follow-up studies that could reshuffle the rankings.
